- Home
- GOF vs RXRX Comparison
GOF vs RXRX Comparison
Compare GOF & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | RXRX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GOF | RXRX |
|---|---|---|
| Price | $8.45 | $3.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.32 |
| AVG Volume (30 Days) | 2.4M | ★ 26.3M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $74,681,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.92 |
| 52 Week Low | $8.40 | $2.77 |
| 52 Week High | $14.02 | $7.18 |
Technical Indicators
Market Signals| Indicator | GOF | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 44.28 |
| Support Level | $8.40 | $2.90 |
| Resistance Level | $10.74 | $3.88 |
| Average True Range (ATR) | 0.18 | 0.44 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 7.63 | 0.29 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.